{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:08:01Z","timestamp":1789996081390,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10096-026-05553-x","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:00:13Z","timestamp":1779768013000},"page":"2615-2635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resistance of gram-negative and gram-positive pathogens to omadacycline: a systematic review"],"prefix":"10.1007","volume":"45","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni D.","family":"Katritsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos M.","family":"Katsikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva D.","family":"Tzvetanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"5553_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","volume":"45","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS (2015) Tetracyclines for Multidrug-Resistant Acinetobacter Baumannii Infections. Int J Antimicrob Agents 45:455\u2013460. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.12.031","journal-title":"Int J Antimicrob Agents"},{"key":"5553_CR2","unstructured":"Food US, Administration D (2018) NUZYRA (Omadacycline) for Injection and Tablets: Highlights of Prescribing Information. U.S. Food and Drug Administration"},{"key":"5553_CR3","unstructured":"Nuzyra | European Medicines Agency (EMA) (2025) Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nuzyra (accessed on 30 October"},{"key":"5553_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01317-22","volume":"67","author":"T Morrisette","year":"2023","unstructured":"Morrisette T, Stamper KC, Lev KL, Kebriaei R, Holger DJ, Abdul-Mutakabbir JC, Kunz Coyne AJ, Rybak MJ (2023) Evaluation of Omadacycline alone and in combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacokinetic\/pharmacodynamic biofilm model. Antimicrob Agents Chemother 67:e01317-22. https:\/\/doi.org\/10.1128\/aac.01317-22","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00522-20","volume":"64","author":"K Begum","year":"2020","unstructured":"Begum K, Bass\u00e8res E, Miranda J, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Rashid T, Eyre DW, Wilcox MH, Alam MJ et al (2020) In vitro activity of Omadacycline, a new tetracycline analog, and comparators against Clostridioides difficile. Antimicrob Agents Chemother 64:e00522-20. https:\/\/doi.org\/10.1128\/AAC.00522-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ph12020063","volume":"12","author":"F Dur\u00e3es","year":"2019","unstructured":"Dur\u00e3es F, Sousa E (2019) Omadacycline: a newly approved antibacterial from the class of tetracyclines. Pharmaceuticals Basel 12:63. https:\/\/doi.org\/10.3390\/ph12020063","journal-title":"Pharmaceuticals Basel"},{"key":"5553_CR7","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S (2016) Discovery, Pharmacology, and Clinical Profile of Omadacycline, a Novel Aminomethylcycline Antibiotic. Bioorg Med Chem 24:6409\u20136419. https:\/\/doi.org\/10.1016\/j.bmc.2016.07.029","journal-title":"Bioorg Med Chem"},{"key":"5553_CR8","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2147\/IDR.S171352","volume":"12","author":"RM Burgos","year":"2019","unstructured":"Burgos RM, Rodvold KA (2019) Omadacycline: a novel aminomethylcycline. Infect Drug Resist 12:1895\u20131915. https:\/\/doi.org\/10.2147\/IDR.S171352","journal-title":"Infect Drug Resist"},{"key":"5553_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens15040396","volume":"15","author":"ME Falagas","year":"2026","unstructured":"Falagas ME, Ragias D, Kontogiannis DS, Romanos LT, Farazi PA (2026) Proposed risk of bias assessment tool for in vitro antimicrobial susceptibility studies. Pathogens 15:396. https:\/\/doi.org\/10.3390\/pathogens15040396","journal-title":"Pathogens"},{"key":"5553_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00542-22","volume":"10","author":"T Abbey","year":"2022","unstructured":"Abbey T, Vialichka A, Jurkovic M, Biagi M, Wenzler E (2022) Activity of Omadacycline alone and in combination against carbapenem-nonsusceptible Acinetobacter baumannii with varying Minocycline susceptibility. Microbiol Spectr 10:e00542-22. https:\/\/doi.org\/10.1128\/spectrum.00542-22","journal-title":"Microbiol Spectr"},{"key":"5553_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/1120009X.2022.2095156","volume":"35","author":"M Abd El-Aziz Gadallah","year":"2023","unstructured":"Abd El-Aziz Gadallah M, El-sayed WM, Hussien MZ, Elheniedy MA, Maxwell SY (2023) In-vitro activity of Plazomicin, Meropenem-Vaborbactam, and Omadacycline against carbapenem-resistant gram-negative isolates in Egypt. J Chemother 35:205\u2013218. https:\/\/doi.org\/10.1080\/1120009X.2022.2095156","journal-title":"J Chemother"},{"key":"5553_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.02546","volume":"10","author":"B Bai","year":"2019","unstructured":"Bai B, Lin Z, Pu Z, Xu G, Zhang F, Chen Z, Sun X, Zheng J, Li P, Deng Q et al (2019) In vitro activity and heteroresistance of Omadacycline against clinical Staphylococcus aureus isolates from China reveal the impact of Omadacycline susceptibility by branched-chain amino acid transport System II carrier protein, Na\/Pi cotransporter family protein, and fibronectin-binding protein. Front Microbiol 10:2546. https:\/\/doi.org\/10.3389\/fmicb.2019.02546","journal-title":"Front Microbiol"},{"key":"5553_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/mdr.2025.0046","volume":"31","author":"AR Bichali","year":"2025","unstructured":"Bichali AR, Piau C, Reissier S, Lecourt M, Collet A, Penven M, Gu\u00e9rin F, Cattoir V (2025) In vitro activity of novel antibiotics against Corynebacterium Spp. clinical isolates responsible for difficult-to-treat infections. Microb Drug Resist 31:211\u2013218. https:\/\/doi.org\/10.1089\/mdr.2025.0046","journal-title":"Microb Drug Resist"},{"key":"5553_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02262-18","volume":"63","author":"CG Carvalhaes","year":"2019","unstructured":"Carvalhaes CG, Huband MD, Reinhart HH, Flamm RK, Sader HS (2019) Antimicrobial activity of Omadacycline tested against clinical bacterial isolates from hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY antimicrobial surveillance program (2013 to 2016). Antimicrob Agents Chemother 63:e02262-18. https:\/\/doi.org\/10.1128\/AAC.02262-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107499","volume":"66","author":"Y Chen","year":"2025","unstructured":"Chen Y, Hong Y, Wang X, Cheng X, Zhu F, Wang H, Wang Z, Jiang S, Chen M, Zhuang H et al (2025) Profiling of Omadacycline resistance in clinical MRSA: A nationwide genomic survey and in vitro evolutionary analysis. Int J Antimicrob Agents 66:107499. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107499","journal-title":"Int J Antimicrob Agents"},{"key":"5553_CR16","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.pathol.2022.09.007","volume":"55","author":"KL Chew","year":"2023","unstructured":"Chew KL, Cabang JC, Teo J (2023) Limited in Vitro Susceptibility of Drug-Resistant Non-Fermenting Gram-Negative Organisms against Newer Generation Antibiotics. Pathol (Phila) 55:583\u2013587. https:\/\/doi.org\/10.1016\/j.pathol.2022.09.007","journal-title":"Pathol (Phila)"},{"key":"5553_CR17","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.2147\/IDR.S473546","volume":"17","author":"Y Du","year":"2024","unstructured":"Du Y, Liu Y, Liu T, Pan F, Mu S, Zhu Y, Gao H, Jing X, Wang X, Liu Y et al (2024) The in Vitro Activity of Omadacycline Alone and in Combination Against Carbapenem-Resistant Klebsiella Pneumoniae. Infect Drug Resist 17:5785\u20135794. https:\/\/doi.org\/10.2147\/IDR.S473546","journal-title":"Infect Drug Resist"},{"key":"5553_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01972-19","volume":"64","author":"J Dubois","year":"2020","unstructured":"Dubois J, Dubois M, Martel J-F (2020) In vitro and intracellular activities of Omadacycline against Legionella pneumophila. Antimicrob Agents Chemother 64:e01972-19. https:\/\/doi.org\/10.1128\/AAC.01972-19","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","volume":"42","author":"I Galani","year":"2023","unstructured":"Galani I, Papoutsaki V, Karaiskos I, Moustakas N, Galani L, Maraki S, Mavromanolaki VE, Legga O, Fountoulis K, Platsouka ED et al (2023) In vitro activities of Omadacycline, Eravacycline, Cefiderocol, Apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020\u20132021: A multicenter study. Eur J Clin Microbiol Infect Dis 42:843\u2013852. https:\/\/doi.org\/10.1007\/s10096-023-04616-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5553_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01471-21","volume":"10","author":"R Han","year":"2022","unstructured":"Han R, Ding L, Yang Y, Guo Y, Yin D, Wu S, Zhi P, Zhu D, Liu Q, Tan X et al (2022) In vitro activity of KBP-7072 against 536 Acinetobacter Baumannii Complex isolates collected in China. Microbiol Spectr 10:e01471-21. https:\/\/doi.org\/10.1128\/spectrum.01471-21","journal-title":"Microbiol Spectr"},{"key":"5553_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jmii.2022.09.009","volume":"56","author":"C-F Huang","year":"2023","unstructured":"Huang C-F, Wang J-T, Chuang Y-C, Sheng W-H, Chen Y-C (2023) In vitro susceptibility of common Enterobacterales to Eravacycline in Taiwan. J Microbiol Immunol Infect 56:358\u2013366. https:\/\/doi.org\/10.1016\/j.jmii.2022.09.009","journal-title":"J Microbiol Immunol Infect"},{"key":"5553_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jgar.2025.04.027","volume":"43","author":"MD Huband","year":"2025","unstructured":"Huband MD, Rhomberg PR, Fedler KA, Blankers C, Anastasiou D, Serio AW, Castanheira M (2025) In vitro activity of Omadacycline against bacterial isolates from bone\/joint infections and rare pathogens in the SENTRY Antimicrobial Surveillance Program (2015\u20132023). J Glob Antimicrob Resist 43:271\u2013284. https:\/\/doi.org\/10.1016\/j.jgar.2025.04.027","journal-title":"J Glob Antimicrob Resist"},{"key":"5553_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/mdr.2019.0423","volume":"27","author":"A Iregui","year":"2021","unstructured":"Iregui A, Landman D, Quale J (2021) Activity of Omadacycline and other tetracyclines against contemporary Gram-Negative pathogens from New York City hospitals. Microb Drug Resist 27:190\u2013195. https:\/\/doi.org\/10.1089\/mdr.2019.0423","journal-title":"Microb Drug Resist"},{"key":"5553_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01907-18","volume":"63","author":"SA Kohlhoff","year":"2019","unstructured":"Kohlhoff SA, Huerta N, Hammerschlag MR (2019) In vitro activity of Omadacycline against Chlamydia pneumoniae. Antimicrob Agents Chemother 63:e01907-18. https:\/\/doi.org\/10.1128\/AAC.01907-18","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR25","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/jac\/dkab141","volume":"76","author":"S-C Kuo","year":"2021","unstructured":"Kuo S-C, Wang Y-C, Tan M-C, Huang W-C, Shiau Y-R, Wang H-Y, Lai J-F, Huang I-W, Lauderdale T-L (2021) In Vitro Activity of Imipenem\/Relebactam, Meropenem\/Vaborbactam, Ceftazidime\/Avibactam, Cefepime\/Zidebactam and Other Novel Antibiotics against Imipenem-Non-Susceptible Gram-Negative Bacilli from Taiwan. J Antimicrob Chemother 76:2071\u20132078. https:\/\/doi.org\/10.1093\/jac\/dkab141","journal-title":"J Antimicrob Chemother"},{"key":"5553_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106377","volume":"58","author":"Y-L Lee","year":"2021","unstructured":"Lee Y-L, Ko W-C, Lee W-S, Lu P-L, Chen Y-H, Cheng S-H, Lu M-C, Lin C-Y, Wu T-S, Yen M-Y et al (2021) In-vitro activity of cefiderocol, cefepime\/zidebactam, cefepime\/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the surveillance of multicenter antimicrobial resistance in Taiwan (SMART) in 2017\u20132020. Int J Antimicrob Agents 58:106377. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106377","journal-title":"Int J Antimicrob Agents"},{"key":"5553_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-025-03967-9","volume":"25","author":"Z Lei","year":"2025","unstructured":"Lei Z, Liu Q, Ma Y, Yang X, Zu H, Li Z, Zhang F, Pu D, Zhang Y, Lu B (2025) In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study. BMC Microbiol 25:255. https:\/\/doi.org\/10.1186\/s12866-025-03967-9","journal-title":"BMC Microbiol"},{"key":"5553_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1089\/mdr.2024.0220","volume":"31","author":"K Li","year":"2025","unstructured":"Li K, Jia H, Gu Y, Xiao Y, Li S, Qu Y, Yang Q (2025) Species distribution and antimicrobial susceptibility of diverse strains within Burkholderia cepacia Complex. Microb Drug Resist 31:154\u2013161. https:\/\/doi.org\/10.1089\/mdr.2024.0220","journal-title":"Microb Drug Resist"},{"key":"5553_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00499-20","volume":"64","author":"JD Lutgring","year":"2020","unstructured":"Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J et al (2020) Antibiotic susceptibility of NDM-producing Enterobacterales collected in the United States in 2017 and 2018. Antimicrob Agents Chemother 64:e00499-20. https:\/\/doi.org\/10.1128\/AAC.00499-20","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.01242-13","volume":"58","author":"AB Macone","year":"2014","unstructured":"Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB (2014) In vitro and in vivo antibacterial activities of Omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127\u20131135. https:\/\/doi.org\/10.1128\/AAC.01242-13","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115054","volume":"97","author":"RE Mendes","year":"2020","unstructured":"Mendes RE, Huband MD, Streit JM, Castanheira M, Flamm RK (2020) Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired Tetracycline resistance mechanisms. Diagn Microbiol Infect Dis 97:115054. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2020.115054","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5553_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab177","volume":"3","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Li L, Liu Q, Zhang J, Huband MD, Lindley JM, Mendes RE (2021) In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation Tetracycline, against clinical isolates with molecularly characterized Tetracycline resistance mechanisms. JAC-Antimicrob Resist 3:dlab177. https:\/\/doi.org\/10.1093\/jacamr\/dlab177","journal-title":"JAC-Antimicrob Resist"},{"key":"5553_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17","volume":"61","author":"MA Pfaller","year":"2017","unstructured":"Pfaller MA, Huband MD, Rhomberg PR, Flamm RK (2017) Surveillance of Omadacycline activity against clinical isolates from a global collection (North America, Europe, Latin America, Asia-Western Pacific), 2010\u20132011. Antimicrob Agents Chemother 61:e00018-17. https:\/\/doi.org\/10.1128\/AAC.00018-17","journal-title":"Antimicrob Agents Chemother"},{"key":"5553_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","volume":"27","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK (2021) Surveillance of Omadacycline Activity Tested against Clinical Isolates from the USA: Report from the SENTRY Antimicrobial Surveillance Program, 2019. J Glob Antimicrob Resist 27:337\u2013351. https:\/\/doi.org\/10.1016\/j.jgar.2021.09.011","journal-title":"J Glob Antimicrob Resist"},{"key":"5553_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/mdr.2024.0215","volume":"31","author":"R Sinha","year":"2025","unstructured":"Sinha R, Jyoti J, Pathak A, Sahu C, Mishra P, Marak RSK, Ghoshal U (2025) Minocycline and Omadacycline Resistance Among Carbapenem-Resistant Gram-Negative Bacteria: Antimicrobial Susceptibility Testing and Molecular Characterization. Microb Drug Resist 31:107\u2013112. https:\/\/doi.org\/10.1089\/mdr.2024.0215","journal-title":"Microb Drug Resist"},{"key":"5553_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3343\/alm.2021.41.3.293","volume":"41","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang B, Xu G, Chen J, Shang Y, Lin Z, Yu Z, Zheng J, Bai B (2021) In vitro activity of the novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, against Moraxella catarrhalis. Ann Lab Med 41:293\u2013301. https:\/\/doi.org\/10.3343\/alm.2021.41.3.293","journal-title":"Ann Lab Med"},{"key":"5553_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-020-02019-8","volume":"20","author":"M Xiao","year":"2020","unstructured":"Xiao M, Huang J, Zhang G, Yang W, Kong F, Kudinha T, Xu Y (2020) Antimicrobial activity of Omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study. BMC Microbiol 20:350. https:\/\/doi.org\/10.1186\/s12866-020-02019-8","journal-title":"BMC Microbiol"},{"key":"5553_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1043736","volume":"13","author":"W Zeng","year":"2022","unstructured":"Zeng W, Zhang X, Liu Y, Zhang Y, Xu M, Wang S, Sun Y, Zhou T, Chen L (2022) In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, Eravacycline, Omadacycline, and Tigecycline against clinical Staphylococcus aureus isolates. Front Microbiol 13:1043736. https:\/\/doi.org\/10.3389\/fmicb.2022.1043736","journal-title":"Front Microbiol"},{"key":"5553_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115651","volume":"103","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Neidig N, Chu T-Y, Divoky C, Carpenter J, Lee-Hsiao C, Threatt H, Sultana R, Bush K (2022) In vitro antibacterial activity of Cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates. Diagn Microbiol Infect Dis 103:115651. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115651","journal-title":"Diagn Microbiol Infect Dis"},{"key":"5553_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN et al (2019) Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 380:517\u2013527. https:\/\/doi.org\/10.1056\/NEJMoa1800201","journal-title":"N Engl J Med"},{"key":"5553_CR41","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1093\/cid\/ciz395","volume":"69","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Steenbergen J, Zhanel GG (2019) Microbiology and Preclinical Review of Omadacycline. Clin Infect Dis 69:S6\u2013S15. https:\/\/doi.org\/10.1093\/cid\/ciz395","journal-title":"Clin Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05553-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05553-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:34:31Z","timestamp":1789994071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05553-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5553"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05553-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None to declare.","order":1,"name":"Ethics","label":"Transparency declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}